


Taiwan's Formosa Pharma inks deal with Adalvo for treatment of ocular inflammation and pain

29 May 2025 | News

Commercialisation of clobetasol propionate ophthalmic suspension, 0.05% (APP13007)



Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Adalvo Limited in the European and Brazilian markets for exclusive rights to the commercialisation of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular surgery.

The licensing agreement with Adalvo includes upfront payment, sales milestones, and profit sharing, with additional considerations throughout the term of the agreement.

APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT[®] nanoparticle formulation platform.

The novel formulation, approved by the US FDA in 2024, enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a US survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007.

The European ophthalmology market reached \$16 billion in 2024, with Germany and the UK leading as the largest markets.

Cataract surgery is among the most common procedures performed in EU hospitals, driving demand for effective post-operative treatments. Looking ahead, the ocular surgery segment is projected to grow to \$38 billion by 2032.